As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to becoming an oncology powerhouse. | More than 4 years after its first ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...